Stem Cell Transplant Reviewed for Peripheral T - Cell Lymphoma
Three - and five - year overall survival similar with allogeneic or autologous HSCT, but transplant - related mortality higher with allogeneic HSCT (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 10, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news

Stem Cell Transplant Reviewed for Peripheral T-Cell Lymphoma
THURSDAY, June 10, 2021 -- For patients with refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), three- and five-year overall survival (OS) and progression-free survival (PFS) are similar with allogeneic or autologous hematopoietic stem... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 10, 2021 Category: Pharmaceuticals Source Type: news

Durham company sees promise in clinical trials for leukemia treatment
A gene therapy company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future. Durham-based Precision BioSciences (Nasdaq: DTIL) last week announced the interim results of the phase 1/2a trial for PBCAR0191, which showed 75 percent of the study participants with treatment-resistant non-Hodgkins lymphoma responded to the company's treatment. PBCAR0191 is an allogeneic chime ric antigen receptor T cell, or CAR-T, therapy that uses… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 8, 2021 Category: Pharmaceuticals Authors: Sonia Waraich Source Type: news

Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma
Basel, 4 June 2021 ‒ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data on its investigational CD20xCD3 T-cell engaging bispecific antibodies, mosunetuzumab and glofitamab, and its first-in-class anti-CD79b antibody-drug conjugate, Polivy® (polatuzumab vedotin), in non-Hodgkin lymphoma (NHL) will be p resented at the 2021 ASCO Annual Meeting from 4-8 June 2021. (Source: Roche Media News)
Source: Roche Media News - June 4, 2021 Category: Pharmaceuticals Source Type: news

Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma
Basel, 4 June 2021 ‒ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data on its investigational CD20xCD3 T-cell engaging bispecific antibodies, mosunetuzumab and glofitamab, and its first-in-class anti-CD79b antibody-drug conjugate, Polivy® (polatuzumab vedotin), in non-Hodgkin lymphoma (NHL) will be p resented at the 2021 ASCO Annual Meeting from 4-8 June 2021. (Source: Roche Investor Update)
Source: Roche Investor Update - June 4, 2021 Category: Pharmaceuticals Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

PET/MRI advances efforts for virtual biopsy in breast cancer
FDG-PET/MRI combined with ultrasound could reduce the need for invasive biops...Read more on AuntMinnie.comRelated Reading: PET imaging shows how COVID vaccines confound cancer detection PET tracers reveal long-term consequences of brain injuries PET/MRI study looks at head injuries and Alzheimer's disease When will PET/MRI live up to its promise? FDG-PET/MRI offers option for pediatric Hodgkin lymphoma (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 27, 2021 Category: Radiology Source Type: news

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with Ukoniq (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ublituximab, the Company’s... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 25, 2021 Category: Drugs & Pharmacology Source Type: news

Dental school researcher gets approval to begin clinical trials for cancer therapy
(Rutgers University) A company founded by Rutgers School of Dental Medicine researcher Scott Kachlany received US Food and Drug Administration (FDA) approval to treat cancer patients with a therapy based on Kachlany's discovery that a protein produced by an oral bacterium can kill leukemia and lymphoma cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

High-Dose Methotrexate of No CNS Benefit in High-Risk DLBCL High-Dose Methotrexate of No CNS Benefit in High-Risk DLBCL
Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have a greater than 10% risk of central nervous system (CNS) relapse.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 19, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Bayer loses appeal of $25 million verdict, making more Roundup lawsuits likely
Bayer lost its appeal of a $25 million ruling that Roundup caused a California man's non-Hodgkins lymphoma. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 17, 2021 Category: Pharmaceuticals Authors: Greg Edwards Source Type: news

NK cells with bispecific antibody show activity against lymphoma cells
(University of Texas M. D. Anderson Cancer Center) Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against CD30+ lymphoma cells, according to a new preclinical study from researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 13, 2021 Category: International Medicine & Public Health Source Type: news

Do variations in pediatric imaging coverage affect patient care?
Pediatric imaging coverage protocols at academic centers vary widely, and fe...Read more on AuntMinnie.comRelated Reading: Noncontrast pituitary MRI effective for pediatric pathology diagnosis Incidental findings common but rarely serious on pediatric brain MRI Imaging findings help AI algorithm detect physical child abuse FDG-PET/MRI offers option for pediatric Hodgkin lymphoma Historical study finds benign bone tumors are common in children (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 12, 2021 Category: Radiology Source Type: news

Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year's meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to he...
Source: Roche Media News - May 11, 2021 Category: Pharmaceuticals Source Type: news

Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Basel, 11 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held 4-8 June, 2021. A total of 132 abstracts that include a Roche medicine will be presented at this year's meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.“We will be presenting data from across our diverse oncology portfolio that has the potential to he...
Source: Roche Investor Update - May 11, 2021 Category: Pharmaceuticals Source Type: news

PET/CT detects major depression in cancer patients
FDG-PET/CT scans can help detect major depression in cancer patients, accordin...Read more on AuntMinnie.comRelated Reading: FDG-PET/CT may increase survival in SCC patients FDG-PET/CT effective for staging in new breast cancer Keto diet improves PET/CT of cardiac sarcoidosis SNMMI provides update on COVID-19 vaccine and PET/CT FDG-PET/MRI offers option for pediatric Hodgkin lymphoma (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 10, 2021 Category: Radiology Source Type: news

UVA's Dr. Michael E. Williams honored nationally for improving lymphoma care
(University of Virginia Health System) For his work to improve patient care and develop new therapies for mantle cell lymphoma (MCL), the Lymphoma Research Foundation has honored UVA Health's Michael E. Williams, MD, with the Mantle Cell Lymphoma Leadership Award. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 6, 2021 Category: Cancer & Oncology Source Type: news

Roche ’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 5 May 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor rec eptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. (Source: Roche Media News)
Source: Roche Media News - May 5, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 5 May 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor rec eptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. (Source: Roche Investor Update)
Source: Roche Investor Update - May 5, 2021 Category: Pharmaceuticals Source Type: news

Karyopharm taps Amgen, Pfizer veteran as CEO
Oncology-focused Karyopharm Therapeutics has a new CEO and president: Richard Paulson, who brings with him a collective 25 years of leadership experience at Pfizer, Amgen and Ipsen North America. Paulson is tasked with commercializing Karyopharm's cancer drugs, one of which has been approved by the U.S. Food and Drug Administration for the blood cancer multiple myeloma as well as diffuse large B-cell lymphoma. Karyopharm (Nasdaq: KPTI) is currently testing the same drug, an oral treatment called… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 3, 2021 Category: American Health Authors: Rowan Walrath Source Type: news

Karyopharm taps Amgen, Pfizer veteran as CEO
Oncology-focused Karyopharm Therapeutics has a new CEO and president: Richard Paulson, who brings with him a collective 25 years of leadership experience at Pfizer, Amgen and Ipsen North America. Paulson is tasked with commercializing Karyopharm's cancer drugs, one of which has been approved by the U.S. Food and Drug Administration for the blood cancer multiple myeloma as well as diffuse large B-cell lymphoma. Karyopharm (Nasdaq: KPTI) is currently testing the same drug, an oral treatment called… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 3, 2021 Category: Biotechnology Authors: Rowan Walrath Source Type: news

Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants
(University of Texas M. D. Anderson Cancer Center) A Phase II trial at MD Anderson tound that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 30, 2021 Category: Cancer & Oncology Source Type: news

Cholestenone shows antibiotic properties against H. pylori
(Shinshu University) Helicobacter pylori, a gram-negative pathogen that has infected half of the world's population is a Group I carcinogen according to the WHO. H. pylori resides in the gastric mucosa causing gastritis, ulcers, gastric cancers and gastric malignant lymphoma. It can be eradicated in most infected people using a combination of three drugs including antibiotics clarithromycin. However drug-resistant H. Pylori is a growing problem and it is expected to develop drugs that exhibit anti-H. pylori activity. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 27, 2021 Category: International Medicine & Public Health Source Type: news

FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas
The product is the first and only CD19-targeted antibody drug conjugate (ADC) available for this disease, and was granted an accelerated approval based on overall response rate.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 26, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Zynlonta (loncastuximab tesirine-lpyl) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
LAUSANNE, Switzerland--(BUSINESS WIRE) APRIL 23, 2021 -- ADC Therapeutics SA (NYSE: ADCT) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynlonta (loncastuximab tesirine-lpyl) for the treatment of adult patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 23, 2021 Category: Drugs & Pharmacology Source Type: news

FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma
On April 23, 2021, the Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 23, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Bas ed on this positive CHMP recommendation, a final decision regarding the approval of Venclyxto in certain patients with untreated AML is expected from the European Commission in the near future.“Today’s...
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news

Vaccines Won ’t Protect Millions of Patients With Weakened Immune Systems
Many cannot produce enough infection-fighting cells to fend off the coronavirus. But researchers are testing one therapy that may help: monoclonal antibodies. (Source: NYT Health)
Source: NYT Health - April 16, 2021 Category: Consumer Health News Authors: Apoorva Mandavilli Tags: your-feed-science Antibodies Coronavirus (2019-nCoV) Vaccination and Immunization Immune System Drugs (Pharmaceuticals) Autoimmune Diseases Rituxan Leukemia & Lymphoma Society Regeneron Pharmaceuticals Inc Source Type: news

AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
Significant reduction found in risk for disease progression/death for C+R versus placebo and rituximab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 13, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

Combo Provides'Broad Benefit' Across NHL Subtypes Combo Provides'Broad Benefit' Across NHL Subtypes
The combination of copanlisib + rituximab led to a reduction in the risk for disease progression/death when compared with rituximab + placebo in patients with relapsed, indolent non-Hodgkin lymphoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

AACR: Copanlisib + Rituximab Slows Relapsed Indolent Lymphoma
TUESDAY, April 13, 2021 -- Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 13, 2021 Category: Pharmaceuticals Source Type: news

Combination-copanlisib-rituximab-significantly-increases-progression-free-survival-patients-relapsed
Copanlisib is the first and only PI3K inhibitor to demonstrate broad and superior efficacy in combination with rituximab in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) compared to rituximab and placebo / Phase III trial CHRONOS-3 showed the combination of copanlisib and rituximab resulted in a 48% reduction in the risk of disease progression or death in patients with iNHL / The strong reduction in risk of progression or death was observed across all prespecified iNHL subtypes / The adverse event (AE) profile of the copanlisib and rituximab combination was manageable and generally consistent with pre...
Source: Bayer Company News - April 10, 2021 Category: Pharmaceuticals Source Type: news

New CAR T approach minimizes resistance, helps avoid relapse in non-Hodgkin's B-cell lymphoma
(University of California - Los Angeles Health Sciences) Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led by researchers at the UCLA found using a bilateral attack achieves a more robust defense and helps avoid relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2021 Category: Cancer & Oncology Source Type: news

Social Factors Affect Treatment for Mantle Cell Lymphoma
Unmarried, less - educated patients less likely to receive autologous hematopoietic cell transplantation (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 9, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news

Social Factors Affect Treatment for Mantle Cell Lymphoma
FRIDAY, April 9, 2021 -- Autologous hematopoietic cell transplantation (AHCT) is associated with a lower likelihood of death among adult mantle cell lymphoma (MCL) patients, but certain sociodemographic factors may affect the selection of candidates... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 9, 2021 Category: Pharmaceuticals Source Type: news

FDA D.I.S.C.O. Burst Edition: Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test
Listen to a soundcast of the March 3, 2021 approval of Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA D.I.S.C.O. Burst Edition: Libtayo (cemiplimab-rwlc) for first-line treatment of patients with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression with no eGFR, anaplastic lymphoma kinase or receptor tyrosine kinase aberrations
Listen to a soundcast of the February 22nd 2021 FDA approval of Libtayo (cemiplimab-rwlc) for first-line treatment of patients with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Excellent outcomes reported for first targeted therapy for pediatric Hodgkin lymphoma
(St. Jude Children's Research Hospital) Results from a collaborative multi-site clinical trial show the success of adding brentuximab vedotin, reducing radiation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 8, 2021 Category: Cancer & Oncology Source Type: news

FDG-PET/CT effective for staging in new breast cancer
FDG-PET/CT scans are a valuable tool for staging women newly diagnosed wit...Read more on AuntMinnie.comRelated Reading: Keto diet improves PET/CT of cardiac sarcoidosis SNMMI provides update on COVID-19 vaccine and PET/CT FDG-PET/MRI offers option for pediatric Hodgkin lymphoma FDG-PET/CT shows COVID-19 vaccine uptake Is there a place for whole-body cancer screening? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 7, 2021 Category: Radiology Source Type: news

Mayo Clinic Minute: Understanding, treating lymphoma
Lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network. The main two subtypes are Hodgkin lymphoma and non-Hodgkin lymphoma. Because of breakthrough research, this once fatal diagnosis has been transformed into a curable condition. In this Mayo Clinic Minute, Dr. Stephen Ansell, a Mayo Clinic hematologist, discusses the [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 30, 2021 Category: Databases & Libraries Source Type: news

EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma
The panel recommends EU approval for duvelisib (Copiktra) for certain patients with chronic lymphocytic leukemia (CLL) or follicular lymphoma.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

What Are Indications for a Ileostomy?
Discussion There are three types of inflammatory bowel disease (IBD): Crohn’s disease (CD) – can affect entire gastrointestinal tract but often is discontinuous (i.e., has skipped areas), has transmural inflammation and disease, has granulomas Ulcerative colitis (UC) – affects the colon, is continuous (i.e., has no skipped areas) and has superficial mucosal ulcerations Unclassified IBD – has chronic colitis but not specific features of CD or UC The specific pathogenesis appears to be multifactorial with having a genetic predisposition (1.6 – 30% risk of developing UC if patient has first deg...
Source: PediatricEducation.org - March 29, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Media News - March 26, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Investor Update - March 26, 2021 Category: Pharmaceuticals Source Type: news

Chugai: Polivy approved for treatment of relapsed or refractory diffuse large B-cell lymphoma in Japan
Dear Investor, Please find attached a press release by Chugai:https://www.roche.com/dam/jcr:886cf513-18db-4809-a7d5-de8b66ca4b0e/en/210324_IR_Chugai_ePolivy_Approval.pdf Do not hesitate to contact us for any further questions. With best regards, (Source: Roche Investor Update)
Source: Roche Investor Update - March 24, 2021 Category: Pharmaceuticals Source Type: news

Cancer symptoms: Painless swellings may be a sign of non-Hodgkin lymphoma
CANCER will affect one in two of us, meaning 50 percent of the British population will get the deadly disease in their lifetime. What are the early warning signs of non-Hodgkin lymphoma? (Source: Daily Express - Health)
Source: Daily Express - Health - March 24, 2021 Category: Consumer Health News Source Type: news

What Are the Warning Signs of Lymphoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 24, 2021 Category: General Medicine Source Type: news

What Is the Survival Rate for NonHodgkin Lymphoma
What Is the Survival Rate for Non-Hodgkin Lymphoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 24, 2021 Category: General Medicine Source Type: news

Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
SOUTH SAN FRANCISCO, Calif., March 22, 2021 -- (Healthcare Sales & Marketing Network) -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering... Biopharmaceuticals, Oncology, Personnel Sutro Biopharma, XpressCF+, multiple myeloma, non-Hodgkin lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2021 Category: Pharmaceuticals Source Type: news